Early Weight Gain Predicting Later Weight Gain Among Depot Medroxyprogesterone Acetate Users
- 1 August 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Obstetrics & Gynecology
- Vol. 114 (2), 279-284
- https://doi.org/10.1097/aog.0b013e3181af68b2
Abstract
OBJECTIVE: To examine if early weight gain in depot medroxyprogesterone acetate (DMPA) users predicts continued excessive weight gain and to identify risk factors of early weight gain in DMPA users. METHODS: Depot medroxyprogesterone acetate users (N=240) were assessed before initiating contraception and every 3 months for 36 months. Early weight gain was defined as more than 5% baseline weight gain within 6 months of DMPA use. Mean weight gain at 6-month intervals was estimated based on early weight gain status (at or below 5% gain compared with above 5% gain). Multiple logistic and mixed-model regression analyses were used. RESULTS: About one-fourth of DMPA users had early weight gain. The mean weight gain of the at or below 5% group and above 5% group was 0.63 kg and 8.04 kg, 1.48 kg and 10.86 kg, and 2.49 kg and 11.08 kg after 12, 24, and 36 months (P<.001 at all observations), respectively. Early weight gainers also had a much steeper slope of weight gain over time than the regular weight gainers (0.35 kg/month compared with 0.08 kg/month, P<.001). Risk factors for early weight gain were body mass index less than 30 (odds ratio [OR] 4.00, 95% confidence interval [CI] 1.513–10.455), parity (OR 2.23, 95% CI:1.040–4.761), and self-reported increased appetite after 6 months of DMPA use (OR 3.06, 95% CI 1.505–6.214). CONCLUSION: Most DMPA users who gain excessive weight experience more than a 5% weight increase within 6 months. These data help physicians predict who is at risk of excessive gain and counsel them appropriately. LEVEL OF EVIDENCE: IIKeywords
This publication has 18 references indexed in Scilit:
- Changes in weight, total fat, percent body fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive useAmerican Journal of Obstetrics and Gynecology, 2009
- Long‐Term Weight Development in Women: A 15‐Year Follow‐up of the Effects of PregnancyObesity Research, 2004
- Weight gain, adiposity, and eating behaviors among adolescent females on depot medroxyprogesterone acetate (DMPA)Journal of Pediatric and Adolescent Gynecology, 2004
- Number of Children Associated with Obesity in Middle-Aged Women and Men: Results from the Health and Retirement StudyJournal of Women's Health, 2004
- Overweight Teens at Increased Risk for Weight Gain While Using Depot Medroxyprogesterone AcetateJournal of Pediatric and Adolescent Gynecology, 2002
- Comparison of weight increase in users of depot medroxyprogesterone acetate and copper IUD up to 5 yearsContraception, 2001
- Postpartum contraceptive use among adolescent mothersPublished by Ovid Technologies (Wolters Kluwer Health) ,2000
- The in Vivo Glucocorticoid and Antiglucocorticoid Actions of Medroxyprogesterone AcetateEndocrinology, 1980
- Contraceptive Use—Efficacy Study Utilizing Medroxyprogesterone Acetate Administered As An Intramuscular Injection Once Every 90 DaysFertility and Sterility, 1973
- Depo-medroxyprogesterone acetate as a contraceptive agent: Its effect on weight and blood pressureAmerican Journal of Obstetrics and Gynecology, 1972